Completed PHASE3 INTERVENTIONAL 2-arm NCT00401531

Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants

Immunogenicity Study of a DTaP IPV Hep B PRP T Combined Vaccine in Comparison to Infanrix Hexa™, Both Concomitantly Administered With Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions Diphtheria Haemophilus Influenzae Type b Hepatitis B Pertussis Polio

Interventions DTaP-HB-IPV and Pneumococcal polysaccharide vaccines DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines

Updated 5 times since 2017 Last updated: Feb 14, 2014 Started: Oct 31, 2006 Primary completion: Nov 30, 2007 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00401531, this PHASE3 trial focuses on Diphtheria and Haemophilus Influenzae Type b and remains completed. Sponsored by Sanofi Pasteur, a Sanofi Company, it has been updated 5 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand
• Khonkaen, Thailand